Needham & Company Maintains a 'Buy' on Alnylam Pharmaceuticals (ALNY); Favorable View Based on Low Valuation
Get Alerts ALNY Hot Sheet
Price: $146.22 +0.73%
Rating Summary:
24 Buy, 13 Hold, 1 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Rating Summary:
24 Buy, 13 Hold, 1 Sell
Rating Trend: Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 17
Join SI Premium – FREE
Needham & Company maintains a 'Buy' on Alnylam Pharmaceuticals (NASDAQ: ALNY).
Needham analyst says, "We have a favorable view towards the stock based on low valuation, a growing clinical pipeline, and a new strategy announced in early 2011 focused on rare diseases. Valuation is attractive given a negative EV ($40M), which in our view does not adequately reflect the value of the company’s RNAi platform and pipeline. RNAi technology development has been a challenge, particularly with respect to delivery. However, we believe Alnylam has made meaningful progress towards establishing utility in a clinical setting."
For more ratings news on Alnylam Pharmaceuticals click here and for the rating history of Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $6.92 yesterday.
Needham analyst says, "We have a favorable view towards the stock based on low valuation, a growing clinical pipeline, and a new strategy announced in early 2011 focused on rare diseases. Valuation is attractive given a negative EV ($40M), which in our view does not adequately reflect the value of the company’s RNAi platform and pipeline. RNAi technology development has been a challenge, particularly with respect to delivery. However, we believe Alnylam has made meaningful progress towards establishing utility in a clinical setting."
For more ratings news on Alnylam Pharmaceuticals click here and for the rating history of Alnylam Pharmaceuticals click here.
Shares of Alnylam Pharmaceuticals closed at $6.92 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Needham Reiterates Buy Rating on Amazon.com (AMZN), Raises Estimates
- Alpine Income Property Trust (PINE) PT Lowered to $18 at Jones Trading
- Needham & Company reiterates Buy rating on Amazon (AMZN), raises estimates
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!